Background Over the last decade, the treatment landscape of metastatic renal cell
carcinoma (mRCC) has evolved tremendously. The outcome of patients with mRCC has …

Introduction: Patients with localised and locally advanced renal cancer experience about
20% recurrence during a five-year follow-up period. The aim of the present study was to …

The risk of developing renal cell carcinoma (RCC) increases with age, and given the
constant gain in life expectancy of the general population, both localized RCC and …

Background New targeted therapeutics approved for metastatic renal cell carcinoma
(mRCC) offer multiple options in each line of therapy; however, there are few prospective …

Background: The relationship between progression-free survival and time to progression
(PFS/TTP) and overall survival (OS) has been demonstrated in a variety of solid tumours but …

ABSTRACT The Metastatic Renal Cell Cancer Registry, a large, nationally representative,
prospective registry of patients with metastatic renal cell carcinoma (mRCC), aims to …

Existing data on the prognosis and clinicopathological features of patients with metastatic
renal cell carcinoma (mRCC) are limited. This study aims to investigate the prognostic value …

Objectives Older patients with metastatic renal cell carcinoma (mRCC) were
underrepresented in pivotal trials. Materials and methods Consecutive patients with mRCC …

For many years, therapy for metastatic renal cell carcinoma (mRCC) was limited to a single
line of cytokine therapy with either interferon or interleukin-2. Relatively recently, the novel …

Abstract Between December 2005 and October 2009, FDA approved six targeted therapies
shown to significantly extend survival for advanced renal cell carcinoma (RCC) patients in …